Research Interests
Jeff Coller is the Bloomberg Distinguished Professor of RNA Biology and Therapeutics at Johns Hopkins University.
His lab has made seminal discoveries in the area of messenger RNA stability and translation. He received his Ph.D. in Cellular and Molecular Biology from the University of Wisconsin, and was a postdoctoral fellow in the Howard Hughes Medical Institute at the University of Arizona. Prior to moving to Johns Hopkins University, Dr. Coller served as Director of the RNA Center at Case Western Reserve University where he held the Henry Willson Payne Distinguished Professorship.
He studies the very essence of life: translation of the genetic code. His work has led to fundamental shifts in the understanding of gene expression by demonstrating that the genetic code is a major determinant of mRNA fate. He is the Co-founder of Tevard Biosciences and WyveRNA Therapeutics. In 2018, Tevard Biosciences was awarded Pfizer’s Golden Ticket award for promising neuroscience startups. His publications have been cited over 6,000 times, and he currently holds numerous patents for RNA-based therapeutic applications.
Titles
- Bloomberg Distinguished Professor, Biomedical Engineering
Education
- Postdoctoral training, Howard Hughes Medical Institute, University of Arizona, 2000-2005
- PhD, Cell and Molecular Biology, The University of Wisconsin – Madison, 1994-2000
- Hon. BS, Biology/Chemistry, The University of Michigan, 1990-1994
Recent Highlights
-
March 12, 2025Johns Hopkins Medicine laboratory scientists say they have developed a potential new way to treat a variety of rare genetic diseases marked by too low levels of specific cellular proteins.
-
December 13, 2023Coller is a groundbreaking genetics researcher whose work has led to fundamental shifts in the understanding of gene expression and to the creation of new therapeutics for treating genetic disorders such as Dravet syndrome.